Context Therapeutics announces first patient dosed in Phase 1 trial of CTIM-76 for CLDN6-positive cancers. Initial data expected 2026. Context Therapeutics Inc. has announced the dosing of the first ...
Context Therapeutics Inc. announced its financial results for the year ending December 31, 2024, highlighting significant developments in its clinical programs and financial stability. The company ...
Context Therapeutics Inc. (NASDAQ:CNTX) is one of the best penny stocks under $1 to buy now. Earlier in June, Context Therapeutics presented a Trial in Progress poster for its Phase 1 clinical trial ...
Context Therapeutics Inc. ("Context” or the "Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T ...
PHILADELPHIA, May 02, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced that the U.S. Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results